200 search results for: type 2 inflammation
Clinical Manifestations Associated With Airway Remodeling in Asthma
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
Multifaceted Role of IL-13 in Airway Remodeling
Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.
Pediatric Asthma Trajectory and Clinical Remission
Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
Impact of Exacerbations in COPD
Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality
Exacerbations Lead to Worsening Lung Function
Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes
Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
